Chardan Capital Predicts Stronger Earnings for CervoMed

Key Points

• Chardan Capital has raised its FY2025 earnings per share (EPS) estimate for CervoMed Inc. to ($2.56), reflecting a slight improvement from the previous estimate of ($2.57), and maintains a "Buy" rating with a price target of $15.00.
• CervoMed reported a quarterly EPS of ($0.70), which was below consensus estimates of ($0.57), but its revenue of $1.76 million surpassed analysts' expectations.
• Institutional investors own 25.15% of CervoMed, with several large firms increasing their positions in the company recently, indicating growing confidence in its future prospects.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Analysts at Chardan Capital raised their FY2025 EPS estimates for shares of CervoMed in a research note issued to investors on Monday, August 11th. Chardan Capital analyst D. Gataulin now anticipates that the company will earn ($2.56) per share for the year, up from their prior forecast of ($2.57). Chardan Capital has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Chardan Capital also issued estimates for CervoMed's FY2026 earnings at ($1.15) EPS.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.13). The business had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.45 million. CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.

CRVO has been the topic of several other research reports. D. Boral Capital increased their price objective on shares of CervoMed from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday. Canaccord Genuity Group raised their price target on shares of CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Finally, Roth Capital set a $16.00 price target on shares of CervoMed and gave the company a "buy" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.43.

CervoMed Trading Down 0.7%

CRVO traded down $0.07 on Thursday, hitting $9.57. 5,754 shares of the company's stock were exchanged, compared to its average volume of 2,094,068. The firm has a market cap of $88.56 million, a PE ratio of -3.68 and a beta of -0.79. CervoMed has a twelve month low of $1.80 and a twelve month high of $20.63. The stock has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.05.

Institutional Trading of CervoMed

A number of large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. acquired a new position in CervoMed in the 1st quarter worth approximately $7,898,000. Woodline Partners LP acquired a new position in CervoMed in the 4th quarter worth approximately $175,000. Nuveen LLC acquired a new position in CervoMed in the 1st quarter worth approximately $312,000. Citizens Financial Group Inc. RI acquired a new position in CervoMed in the 1st quarter worth approximately $244,000. Finally, Avantax Advisory Services Inc. acquired a new position in CervoMed in the 1st quarter worth approximately $238,000. 25.15% of the stock is currently owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.